Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have earned an average rating of “Hold” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $6.73.
A number of equities research analysts have issued reports on the company. Wedbush reaffirmed a “neutral” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research report on Tuesday. BMO Capital Markets increased their price target on Fate Therapeutics from $6.00 to $7.00 and gave the company a “market perform” rating in a research report on Tuesday, February 27th. Oppenheimer reaffirmed a “market perform” rating on shares of Fate Therapeutics in a research report on Tuesday, February 27th. Barclays increased their price target on Fate Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research report on Thursday, April 11th.
Get Our Latest Research Report on FATE
Institutional Inflows and Outflows
Fate Therapeutics Price Performance
Shares of Fate Therapeutics stock opened at $3.80 on Monday. The business has a 50-day moving average of $6.73 and a 200 day moving average of $4.56. Fate Therapeutics has a 12 month low of $1.63 and a 12 month high of $8.83. The stock has a market capitalization of $432.52 million, a price-to-earnings ratio of -2.32 and a beta of 1.66.
Fate Therapeutics (NASDAQ:FATE – Get Free Report) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. The company had revenue of $1.68 million during the quarter, compared to analysts’ expectations of $0.85 million. Fate Therapeutics had a negative return on equity of 38.17% and a negative net margin of 253.30%. During the same period last year, the business posted ($0.58) EPS. Equities research analysts anticipate that Fate Therapeutics will post -1.94 earnings per share for the current year.
About Fate Therapeutics
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Further Reading
- Five stocks we like better than Fate Therapeutics
- What does consumer price index measure?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Ride Out The Recession With These Dividend Kings
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.